

The 35th Annual Meeting of the Japanese Breast Cancer Society Congress

A) Basic Science	
A-01	Genomics
A-02	Epigenetics
A-03	Oncogenes / Tumor Suppressor Genes
A-04	Hormone / Hormone Receptor
A-05	Cell Cycle / DNA Damage and Repair
A-06	Transcriptional Regulation and Signal Transduction
A-07	Drug Resistance
A-08	Cancer Stem Cells
A-09	Invasion, Metastasis
A-10	Microenvironment / Angiogenesis
A-11	Tumor Immunology
A-12	micro RNA
A-13	Others (Basic Science)
B) Screening and Prevention	
B-01	Screening Mammography
B-02	Screening Ultrasound
B-03	Improvement of Screening rate, Promotion activities
B-04	Screening MRI
B-05	Screening by liquid
B-06	Secondary Examination (Detailed Examination)
B-07	Prevention
B-08	Screening under the Circumstance of COVID-19
B-09	Others (Screening / Prevention)
C) Diagnostic Imaging	
C-01	Mammography
C-02	Ultrasonography
C-03	MRI
C-04	CT / PET-CT
C-05	New Imaging modality
C-06	Others (Diagnostic Imaging)

D) Pathological Diagnosis	
D-01	Benign Tumor
D-02	Borderline Lesions / Difficult to Distinguish Lesions
D-03	Non-invasive Cancer
D-04	Invasive Cancer
D-05	Special Type
D-06	Paget's Disease
D-07	Non-epithelial or Unclassifiable Tumors
D-08	Assessment of Surgical Margin
D-09	Sentinel Lymph Node Diagnosis
D-10	OSNA / Intraoperative Diagnosis
D-11	Therapeutic Effect of Preoperative Systemic Therapy
D-12	Primary and Metastatic Lesions
D-13	ER / PgR / HER2 / Ki67 / PD-L1 testing
D-14	Cytology
D-15	Molecular Imaging
D-16	Others (Pathological Diagnosis)
E) Intervention	
E-01	US-guided biopsy
E-02	Stereotactic biopsy
E-03	Others (Intervention)
F) Biomarker	
F-01	Prognostic Factor
F-02	Predictive Factor
F-03	Others (Biomarker)
G) Multi gene panel / Liquid biopsy	
G-01	Gene Panel Testing
G-02	Liquid Biopsy
G-03	Others (Gene Panel / Liquid Biopsy)
H) Social Health Medicine	
H-01	Medical Epidemiology, Social Epidemiology
H-02	Genetic Medical Research
H-03	Health Economics
H-04	Health Informatics, Preventive Medicine

I) Women's Health	
I-01	Risk Factor, Prevention
I-02	Bone Health
I-03	Preservation of Fertility
J) Hereditary Breast Cancer	
J-01	Genetic Testing
J-02	Genetic Counseling
J-03	Biology, Clinico-Pathological Feature
J-04	Surveillance, Risk reduction surgery
J-05	Approach to the Family Member
J-06	Others (Treatment of Hereditary Breast Cancer)
K) Surgical Treatment	
K-01	Sentinel Lymph Node Biopsy
K-02	Preoperative Systemic Therapy and Sentinel Lymph Node Biopsy
K-03	Breast-conserving Surgery
K-04	Surgical Treatment for Ipsilateral Breast Tumor Recurrence
K-05	Minimally Invasive Surgical Treatment
K-06	Non-surgical Ablation
K-07	Breast-conserving Surgery and Cosmesis
K-08	Surgical Treatment for Locoregional Recurrence
K-09	Surgical Treatment for Distant Metastatic Lesions
K-10	Postoperative Surveillance
K-11	Medical Equipment
K-12	Others (Surgical Treatment)
L) Oncoplastic Surgery / Breast Reconstruction	
L-01	Oncoplastic Surgery
L-02	Breast Reconstruction

The 35th Annual Meeting of the Japanese Breast Cancer Society Congress

M) Radiation Therapy	
M-01	Radiation Therapy after Breast Conserving Therapy
M-02	Postmastectomy Radiation Therapy
M-03	Adverse Events due to Radiation Therapy
M-04	New Radiation Therapy Technology, Method, Equipment
M-05	Radiation Therapy for Metastasis / Recurrence
M-06	Radiation Therapy Nursing
M-07	Others (Radiation Therapy)
N) Systemic Therapy (Preoperative, Postoperative)	
N-01	Preoperative Hormone Therapy
N-02	Preoperative Chemotherapy
N-03	Preoperative Molecular Targeted Therapy
N-04	Postoperative Hormone Therapy
N-05	Postoperative Chemotherapy
N-06	Postoperative Molecular Targeted Therapy
N-07	Immune Checkpoint inhibitors
N-08	Hormone Receptor Positive
N-09	HER2 Positive
N-10	Triple Negative
N-11	New Drug
N-12	Others (Systemic Therapy, Pre- and Postoperative)
O) Systemic Therapy(Metastasis, Recurrence)	
O-01	Hormone Therapy
O-02	Chemotherapy
O-03	Molecular Targeted Therapy
O-04	Immune Checkpoint Inhibitors
O-05	Hormone Receptor Positive
O-06	HER2 Positive
O-07	Triple Negative
O-08	New Drug
O-09	Others (Systemic Therapy, Metastasis and Recurrence)

P) Clinical Trials	
P-01	Clinical Trials (Systemic Therapy)
P-02	Clinical Trials (except Systemic Therapy)
P-03	Clinical Trials Currently in Progress
Q) Medication Management, Guidance,Safety Management	
Q-01	Medication Management, Guidance
Q-02	Safety Management
Q-03	Others (Medication Management, Guidance, Safety Management)
R) Team Medicine / Medical Cooperation	
R-01	Satisfaction of Patients, Families, and Medical staff
R-02	Supportive Care
R-03	Lymphedema
R-04	The Role of Pharmacists
R-05	The Role of Nurses
R-06	Medical IT
R-07	Medical Cooperation
R-08	Others (Team Medicine / Medical Cooperation)
S) Medical Treatment for Specific Patients and Pathophysiology	
S-01	Juvenile Breast Cancer
S-02	Elderly Breast Cancer
S-03	Male Breast Cancer
S-04	Bilateral Breast Cancer
S-05	Special Histopathological Type
S-06	Inflammatory Breast Cancer
S-07	Locally Advanced Breast Cancer
S-08	Occult Breast Cancer
S-09	Treatment of Breast Cancer Patients with Comorbidity
S-10	Others (Medical Treatment for Specific Patients and Pathophysiology)

T) Supportive Care	
T-01	Symptom Relief
T-02	Psychological Support
T-03	Social support, QOL Improvement
T-04	Wearable Device
T-05	Survivorship
T-06	Psycho-oncology
T-07	Advanced Care Planning
T-08	Patient Support Activities, Patient Groups, Family Support
T-09	Others (Supportive Care)
U) Artificial Intelligence	
U-01	Omics Data
U-02	Clinical Application (Diagnosis)
U-03	Others (Artificial Intelligence)
V) Nursing	
V-01	Nursing for early breast cancer
V-02	Nursing for advanced and recurrent breast cancer
V-03	Others (Nursing)
W) Lifestyle / Work Style / Education	
W-01	Work Style Reform, Task Shift
W-02	Education, Human Resources Development
W-03	Others (Lifestyle / Work Style / Education)
X) Case Report	
X-01	Diagnosis (Pathology, Images, etc.)
X-02	Surgical Treatment
X-03	Drug Therapy
X-04	Radiation Therapy
X-05	Palliative Medicine
X-06	Clinical Course / Pathology
X-07	Nursing
X-08	Others (Case Report)